Loading...
XSHE
300705
Market cap1.14bUSD
Dec 05, Last price  
16.08CNY
1D
-0.19%
1Q
-11.16%
IPO
174.20%
Name

Hunan Jiudian Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300705 chart
P/E
15.70
P/S
2.74
EPS
1.02
Div Yield, %
2.79%
Shrs. gr., 5y
8.44%
Rev. gr., 5y
25.97%
Revenues
2.93b
+8.85%
241,413,229266,489,389290,492,436376,400,199534,515,072801,375,318924,061,197978,159,1321,627,664,9422,326,215,8672,692,511,4602,930,677,498
Net income
512m
+39.13%
25,268,02137,792,56544,642,78554,527,28168,573,37771,985,02055,065,85382,259,768204,245,777269,700,151368,260,790512,377,174
CFO
746m
+73.10%
30,692,79030,107,64432,195,18355,182,57280,419,42268,233,50490,740,744149,994,591190,871,610268,988,603431,185,028746,364,584
Dividend
May 24, 20240.4494 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hunan Jiudian Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers antiallergic, anti-infective, and anti-inflammatory drugs; analgosies and gynecological medication products; digestive system products; chemical and Chinese patent medicines; medical instruments; APIs; and other products. It also provides outsourcing services for tablets, capsules, granules, oral solutions, syrups, etc. Hunan Jiudian Pharmaceutical Co., Ltd. is based in Changsha, China.
IPO date
Oct 10, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT